Can a targeted antibody boost kidney remission in lupus?
Disease control
Not yet recruiting
This phase 3 trial is testing whether adding the drug obinutuzumab to the standard treatment (mycophenolate mofetil and corticosteroids) can improve outcomes for people with active lupus nephritis, a serious kidney complication of lupus. The study will enroll 70 adults aged 18-65…
Phase: PHASE3 • Sponsor: Zhao Minghui • Aim: Disease control
Last updated Aug 18, 2026 05:00 UTC